Samir R. Patel - 06 Mar 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
06 Mar 2025
Net transactions value
+$1,365,000
Form type
4
Filing time
10 Mar 2025, 17:00:10 UTC
Previous filing
07 Jan 2025
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $455,000 +406,250 +15% $1.12 3,031,005 06 Mar 2025 PranaBio Investments LLC F1, F2
holding AKTX American Depositary Shares representing Ordinary Shares 45,698 06 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Series A Warrants (Right to Buy) Award $455,000 +406,250 $1.12 406,250 06 Mar 2025 American Depositary Shares representing Ordinary Shares 406,250 $0.8700 PranaBio Investments LLC F1, F2
transaction AKTX Series B Warrants (Right to Buy) Award $455,000 +406,250 $1.12 406,250 06 Mar 2025 American Depositary Shares representing Ordinary Shares 406,250 $0.8700 PranaBio Investments LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On March 6, 2025, the Reporting Person acquired 406,250 ADS and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Remarks:

Exhibit 24 - Power of Attorney